Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 3890478)

Published in J Korean Med Sci on December 26, 2013

Authors

Soo-Jeong Kim1, June-Won Cheong1, Yoo Hong Min1, Young Jin Choi2, Dong-Gun Lee3, Je-Hwan Lee4, Deok-Hwan Yang5, Sang Min Lee6, Sung-Hyun Kim7, Yang Soo Kim8, Jae-Yong Kwak9, Jinny Park10, Jin Young Kim11, Hoon-Gu Kim12, Byung Soo Kim13, Hun-Mo Ryoo14, Jun Ho Jang15, Min Kyoung Kim16, Hye Jin Kang17, In Sung Cho18, Yeung Chul Mun19, Deog-Yeon Jo20, Ho Young Kim21, Byeong-Bae Park22, Jin Seok Kim1

Author Affiliations

1: Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea.
2: Department of Hematology/Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
3: Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
4: Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
5: Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
6: Department of Internal Medicine, Busan Paik Hospital, Inje University, Busan, Korea.
7: Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
8: Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
9: Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.
10: Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
11: Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
12: Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
13: Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
14: Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea.
15: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
16: Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
17: Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
18: Department of Internal Medicine, Eulji University Hospital, Daejeon, Korea.
19: Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
20: Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
21: Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
22: Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.

Associated clinical trials:

Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients | NCT01060462

Articles cited by this

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis (2008) 20.88

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med (1999) 9.84

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med (2002) 7.85

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis (2009) 4.09

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis (2007) 3.96

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant (2010) 3.46

The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica (2006) 3.41

Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood (2001) 3.14

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis (2011) 2.89

Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis (2008) 2.26

Antifungal therapy in patients with fever and neutropenia--more rational and less empirical? N Engl J Med (2004) 2.26

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica (2009) 1.99

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med (2001) 1.97

Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev (2008) 1.88

Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis (2007) 1.83

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol (2007) 1.82

Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis (2011) 1.70

Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis (2004) 1.58

Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw (2012) 1.35

Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med (2011) 1.32

Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol (2012) 1.23

Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol (2011) 1.10

The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood (2011) 0.94

Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan. Int J Hematol (2009) 0.90

Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever. Korean J Intern Med (2006) 0.86

Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol (2006) 0.83

Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie (2007) 0.83

Articles by these authors

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome. Eur J Haematol (2015) 1.41

Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice Guidelines. J Korean Med Sci (2014) 0.92

VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci (2012) 0.91

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica (2016) 0.90

A multi-center, phase ii clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat (2005) 0.87

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin. J Breast Cancer (2015) 0.85

A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib. Ann Lab Med (2014) 0.84

Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. J Korean Med Sci (2016) 0.82

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget (2016) 0.82

A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow. Blood Res (2014) 0.82

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Cancer Res Treat (2014) 0.80

Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. Liver Int (2015) 0.79

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. Blood Res (2014) 0.79

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. Cancer Res Treat (2016) 0.78

Guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med (2015) 0.78

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget (2016) 0.78

Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean J Intern Med (2016) 0.77

HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT. Blood Res (2015) 0.76

Clinical Significance of Peroxisome Proliferator-Activated Receptor γ and TRAP220 in Patients with Operable Colorectal Cancer. Cancer Res Treat (2015) 0.76

Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation. Blood Res (2015) 0.75

Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis. Ann Lab Med (2016) 0.75

Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. Blood Res (2015) 0.75

Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia. Korean J Intern Med (2015) 0.75

Immunophenotypic markers in adult acute lymphoblastic leukemia: the prognostic significance of CD20 and TdT expression. Blood Res (2015) 0.75

Oncologists' Experience with Patients with Second Primary Cancer and the Attitudes toward Second Primary Cancer Screening: A Nationwide Survey. Cancer Res Treat (2015) 0.75

A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: a single center study in Korea. Blood Res (2016) 0.75

Submicroscopic deletions of immunoglobulin heavy chain gene (IGH) in precursor B lymphoblastic leukemia with IGH rearrangements. Ann Lab Med (2014) 0.75

Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. PLoS One (2016) 0.75

Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. Oncotarget (2016) 0.75

Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci (2016) 0.75

Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. Korean J Intern Med (2016) 0.75

Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5. Oncotarget (2016) 0.75

Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. Ann Hematol (2016) 0.75

Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. Asia Pac J Clin Oncol (2016) 0.75

Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. Oncotarget (2017) 0.75

Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Eur J Haematol (2020) 0.75

Hematopoietic stem cell mobilization: current status and future perspective. Blood Res (2017) 0.75

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Oncotarget (2017) 0.75

Incidence, characteristics, and treatment outcomes of mycobacterial diseases in transplant recipients. Transpl Int (2016) 0.75